AIM ImmunoTech (AIM) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.2 million vs $3.4 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | SLXN |
|---|---|---|
| Share price | $0.1796 | $0.2349 |
| Market cap | $7.17M | $3.40M |
| 1-day change | -1.75% | -7.37% |
| EPS (TTM) | $-2.98 | $-27.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $40.70 |
| 52-week low | $0.17 | $0.222 |
| Distance from 52-week high | -93.57% | -99.42% |
| Analyst consensus | none | none |
| Avg. price target upside | +2266.37% | +2028.57% |
| Average volume | 4.70M | 9.90M |
| Shares outstanding | 39.89M | 14.47M |
| Employees | 19 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AIM ImmunoTech is about 2.1 times larger than Silexion Therapeutics by market value ($7.17M vs $3.40M).
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
AIM vs SLXN FAQ
Which is bigger, AIM ImmunoTech or Silexion Therapeutics?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.17M compared with $3.40M for Silexion Therapeutics (SLXN).
Are AIM ImmunoTech and Silexion Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.